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BACKGROUND: Despite the multitude of available treatments, glioblastoma (GBM)
remains an aggressive and uniformly fatal tumor. Laser interstitial thermal therapy (LITT)
is a novel, minimally invasive treatment that holds promise for treating patients with
GBM who are not candidates for traditional open craniotomy. However, due to the recent
introduction of LITT into clinical practice, large series that evaluate safety and long-term
outcomes after LITT are lacking.
OBJECTIVE: To present our institution’s series of over 50 GBM patients treated with LITT,
with regard to safety, efficacy, and outcomes.
METHODS:We performed a retrospective descriptive study of patients with histologically
proven GBMwho underwent LITT. Data collected included demographics, tumor location
and volume, tumor genetic markers, treatment volume, perioperative complications, and
long-term follow-up data.
RESULTS: We performed 58 LITT treatments for GBM in 54 patients over 5.5 yr. Forty-
one were recurrent tumors while 17 were frontline treatments. Forty GBMs were lobar in
location, while 18 were in deep structures (thalamus, insula, corpus callosum). Average
tumor volume was 12.5 ± 13.4 cm3. Average percentage of tumor treated with the
yellow thermal damage threshold (TDT) line (dose equivalent of 43◦C for 2 min) was
93.3% ± 10.6%, and with the blue TDT line (dose equivalent of 43◦C for 10 min) was
88.0% ± 14.2%. There were 7 perioperative complications (12%) and 2 mortalities (3.4%).
Median overall survival after LITT for the total cohort was 11.5mo, andmedian progression-
free survival 6.6 mo.
CONCLUSION: LITT appears to be a safe and effective treatment for GBM in properly
selected patients.
KEY WORDS: Laser ablation, Laser interstitial thermal therapy, LITT, Glioblastoma, GBM, MRI, Brain tumors,
Thermoablation
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G lioblastoma (GBM) is the most commonprimary brain tumor and remains auniformly fatal disease. Despite the
multitude of therapies available to GBM
patients, median survival is only 14 mo.1,2
Surgery is usually the initial treatment of choice,
and there is mounting evidence that a greater
extent of resection is associated with better
overall survival (OS).3,4 However, many patients
reach a point where additional craniotomies are
no longer feasible. Additionally, many patients
are not good candidates for traditional surgery
at the time of initial diagnosis, and typically
undergo biopsy followed by chemoradiation
without any “direct” cytoreductive treatment.








niversity in St. Louis user on 14 N
ovem
ber 2020
LITT FOR GLIOBLASTOMA—SAFETY, EFFICACY, OUTCOMES
Laser interstitial thermal therapy (LITT) has emerged as a novel
treatment for a variety of intracranial lesions, including GBM.5-8
This technology uses a laser-tip probe, inserted into the centroid
of a brain lesion, to produce a controlled thermal injury by heating
surrounding tissue. Real-timemagnetic resonance imaging (MRI)
thermometry allows for continuous monitoring of the ablation
zone, and ablation can be stopped at any time. LITT is especially
suitable for many patients with GBM for several reasons. The
recurrent and often multifocal nature of the disease means clini-
cians are often faced with the problem of deep or difficult-to-
access lesions. Despite the successes of multiple craniotomies for
resection, factors like advancing age, comorbidity, and inevitable
decline in functional status lead to a point beyond which open
surgery is no longer appropriate. LITT therefore offers promise
as a direct cytoreductive technique that is minimally invasive,
effective, and less morbid than open craniotomy.
Previous series of LITT are limited by small sample sizes and
short follow-up, primarily due to the fairly recent introduction
of this technology in neurosurgery. The object of this study is
to report on safety, efficacy, and outcomes of LITT for GBM
on a cohort of 54 patients for whom follow-up data are largely
complete.
METHODS
We retrospectively reviewed all patients with a diagnosis of GBMwho
underwent LITT between 2010 and 2016 at our institution. Institutional
Review Board (IRB) approval was obtained for human subject research.
Individual patient consents were not sought, as this was a descriptive
retrospective study with all data anonymized. All patients with histologi-
cally proven GBM who underwent LITT were eligible. Information was
collected from electronic records, deidentified, and included age, sex,
tumor location, prior treatments, indication for LITT, complications,
and follow-up data. Genetic data were collected from pathology reports
as available. Two patients in whom the procedure was aborted due to
issues unrelated to the procedure itself were excluded.
The database was maintained in Microsoft Excel (Microsoft Corpo-
ration, Redmond, Washington). Statistical analysis was performed in
Excel and MATLAB (Mathworks Inc., Natick, Massachusetts). The
Student’s t-test was used to compare continuous variables between
groups, and the log-rank test for groups was used to compare survival
curves. A threshold (alpha) of 0.05 was used to indicate statistical
significance.
Our institution primarily utilizes the Monteris R© laser ablation system
(Monteris Medical Corporation, Plymouth, Minnesota). Using the
stereotactic MRI on the workstation, a three-dimensional (3D) tumor
volume is constructed for volumetric analysis. During ablation, real-
time MRI thermometry tracks the progress of the expanding ablation
zone. The ablation zone is characterized by the yellow thermal damage
threshold (TDT) line, signifying a dose equivalent of 43◦C for 2 min,
and by the blue TDT line, signifying a dose equivalent of 43◦C for
10 min (Figure 1). The yellow and blue zones, taken over many slices, are
used to construct a 3D model of the ablation zone. The overlap of the
tumor volume and ablation zones (yellow and blue) yields an ablation
percentage.
FIGURE 1. TDT lines. Image during laser ablation, demonstrating tumor
volume (constructed manually on Monteris R© [Plymouth, Minnesota] propri-
etary software at the time of surgery) and yellow and blue thermal damage
threshold (TDT) lines (derived from real-time MRI thermometry).
Our paradigm for LITT candidate selection has been previously
described9,10 and will be briefly reviewed here. Broadly speaking, lesions
that are favorable for LITT are (1) deep seated, (2) spherical or oblong
such that the laser probe can be passed through the long axis of the lesion,
(3) well circumscribed, and (4) positioned such that a safe trajectory
avoiding critical structures/tracts can be designed. Transgression of
vascular planes (Sylvian fissure, sulci) and ventricles is avoided. Lesions
unfavorable for LITT include hypervascular lesions, diffuse lesions
involving bilateral or multiple lobes, and very large lesions in which
treatment would be subtotal. Lesions in eloquent or constricted locations
(basal ganglia, posterior fossa) are more difficult to target, although this
was not a contraindication to treatment. Finally, technical considerations
include patient positioning, the profile of the laser apparatus, and patient
body habitus, which together must fit into the MRI bore.
GBMs in deep or difficult-to-access areas that fit the above criteria
were ideal candidates for frontline LITT. If a tissue diagnosis had not
yet been obtained, stereotactic needle biopsy was performed through
the same trajectory prior to placement of the laser probe. In the case
of recurrent GBMs, most had already undergone at least 1 open surgery
and chemoradiation. Although there is evidence for the utility of multiple
craniotomies for recurrent GBM,11-13 most patients reach a point where
surgical morbidity is too great. While these lesions could technically
be resected again via open surgery, patient factors such as declining
functional status, chronic steroid use, deconditioning from chronic
illness, and thinned scalp made open surgery unfavorable. These patients
typically go on to receive bevacizumab or other second-line agents.14-16
Selected patients from this group were offered LITT for their recurrent
GBM to be followed by second-line agents, after multidisciplinary review
at our institutional tumor board.
All patients were observed in the neuro intensive care unit (ICU)
postoperatively and received perioperative antibiotics, antiepileptic
medication, and dexamethasone. Dexamethasone was generally tapered
over 1 to 3 wk based on surgeon’s clinical judgment, accounting for
factors such as tumor/ablation volume, surrounding edema, and steroid
side effects.


















Age (mean ± SD) 58.8 ± 10.8
Lesions treated 58 100.0%
Primary 17 29.3%
Recurrent 41 70.7%
First recurrence 35 85.4%












None/biopsy only 17 29.3%
Chemoradiation only 4 6.9%
Resection(s) + 33 56.9%
chemoradiation
Prior LITT only 1 1.7%
Chemoradiation + LITT 1 1.7%






Other (eg, 10 17.2%
tumor-treating
fields, vaccines)
LITT, laser interstitial thermal therapy
RESULTS
A total of 58 LITT treatments were performed in 54 patients
with a histological diagnosis of GBM (Table 1). All cases were
performed by one of two surgeons (ECL—77% and AHK—
23%). There were 37 males and 17 females. Average age was
58.8 (± 10.8) yr, with a range of 35 to 78 yr. Average American
Society of Anesthesiologists (ASA) grade (1-6) preoperatively was
2.6 (± 0.6); ASA grade was not significantly different between the
primary and recurrent groups (mean 2.7 vs 2.5, P = 0.15). Mean
follow-up time was 11.5± 7 mo; only 8 patients in the cohort are
still alive at present (14%) and only one was lost to follow-up. Of
58 treatments, 17 were frontline for primary GBM as determined
by biopsy, either previously or concurrently with LITT. Forty-one
treatments were for recurrent GBM; the majority (33, 80.4%)
FIGURE 2. Lesion locations. Pre- and postoperative imaging demonstrating
successful radiographic response for tumors in A, left posterior thalamic and B, left
frontal locations. Magnetic resonance-safe metal artifact is noted on the patient’s
right side in B.
TABLE 2. Genetic Markers
Total number with
Genetic marker n known status %
IDH-1 (R132) mutation 2 45 4.4
MGMTmethylation 21 45 46.6
1p19q codeletion 4 23 17.4
EGFR amplification 12 27 44.4
had surgical resection(s) and standard chemoradiation prior to
LITT. Four patients had only chemoradiation prior to LITT. Four
patients had prior LITT treatments; of these, 3 underwent repeat
ablation for recurrence and 1 was the second stage of a planned
two-stage procedure.
Anatomic locations of lesions were widely variable (Figure 2A
and 2B). The majority of lesions were lobar, located in the frontal
(n = 14), temporal (n = 8), parietal (n = 9), occipital (n = 1), or
in multiple contiguous lobes (n = 8). Other locations included
corpus callosum (n = 8), insular (n = 2), and thalamic (n = 8)
GBMs
Certain genetic studies were available for subgroups of GBM
patients (Table 2). These included isocitrate dehydrogenase-1
R132 (IDH-1) mutation, O[6]-methylguanine-DNA methyl-
transferase (MGMT) promotermethylation, chromosome 1p and
19q codeletion, and epidermal growth factor receptor (EGFR)
amplification. Only 2 patients harbored IDH-1 mutations out
of 45 whose mutation status was known (4.4%). Similarly, 21
patients out of 45 showed MGMT methylation (46.6%), 4 out
of 23 showed 1p19q deletion (17.4%), and 12 out of 27 showed
EGFR amplification (44.4%).
LITT was chosen primarily due to lesion location in 19 cases
(32.8%), while advanced age, recurrence after prior treatments,
and/or poor functional status were the primary reason for LITT
in 39 cases (67.2%).
Multiple trajectories were used during some LITT treatments
(Table 3). Themajority of treatments involved one trajectory only
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TABLE 3. Surgical Information
n %
Number of trajectories used




Number of cases with 4 6.9%
multiple LITT treatments
Surgery time (min) 240 ± 125
Tumor volume (mL) 12.5 ± 13.4
Min 0.27
Max 62.77








LITT, laser interstitial thermal therapy; IDH-1 (R132), isocitrate dehydrogenase-1, arginine
132; MGMT, O[6]-methylguanine-DNA methyltransferase promoter; 1p19q, chromo-
somes 1p and 19q; EGFR, epidermal growth factor receptor
(n = 49, 84.4%). Seven cases involved two trajectories (12.0%),
and 2 cases involved three trajectories (3.4%). Operating room
time—defined as the time from skin puncture to the application
of the final dressing—varied from 93 to 648 min (mean 240
min, median 223 min). Volumetric data were available for 50
of 58 cases; the following data refer to this subgroup. Average
tumor volume was 12.5± 13.4 cm3. Average percentage of tumor
treated with the yellow TDT line was 93.3 ± 10.6%, and with
the blue TDT line, 88.0 ± 14.2%. Thirty-eight patients (76%)
had at least 90% of tumor volume treated by the yellow TDT
line, and 33 patients (66%) had at least 90% of tumor volume
treated by the blue TDT line. Twenty-one patients (42%) had
total or supratotal ablation by the yellow TDT boundary, and 10
patients (17%) had total or supratotal ablation by the blue TDT
boundary. Ablation was terminated in case of encroachment on
eloquent regions or the inability to reach parts of the lesion due
to fiber placement. MRI was routinely obtained on postablation
day one for evaluation of ablation success, and to establish a post-
LITT baseline. Average ICU length of stay for all patients was
1.7 ± 2.8 d, and average total hospital stay was 3.2 ± 4.6 d; this
figure includes the earliest LITT patients at our institution. We
have previously reported that the length of stay tends to decline as
providers become more familiar with post-LITT patients’ clinical
course.8
There were 9 complications within 30 d of procedure leading
to further procedures, unexpected readmission, or transfer back
to the ICU, or a rate of 15.5%. These consisted of complications
from cerebral edema (n = 3), seizures (n = 3), hydrocephalus
(n = 1), hyponatremia (n = 1), and infection (n = 1). There
were 2 mortalities (3.4%). In cases without complications, mean
tumor volume was 11.7 cm3; in cases with complications, the
mean volume of tumor was 15.5 cm3; this difference was not
significant (P = 0.20).
Median OS after LITT for the total cohort was 11.5 mo
(95% confidence interval (CI) 8.5-12.8 mo, range 0-34.2 mo),
and median progression-free survival (PFS) was 6.6 mo (95%
CI 4.3-7.7 mo, range 0-32.0 mo). These groups were further
broken down as follows. For primary GBMs treated with LITT
as a frontline therapy (n = 17), OS was 9.1 mo (95% CI 4.2-
14.2 mo, range 0-25.4 mo) and PFS was 3.6 mo (95% CI
FIGURE 3. A, Overall and B, PFS in primarily treated vs recurrent GBM after LITT. OS for primarily treated vs recurrent GBM was 9.1 and 11.8 mo, respectively; PFS
was 3.6 and 7.3 mo, respectively. There were no statistically significant differences.












FIGURE4. OS in primarily treated vs recurrent GBM from time of histologic
diagnosis. OS for the primarily treated group was 9.1 mo, and for the recurrent
group, 22.3 mo (P < 0.0001).
0.37-7.67mo, range 0-19.3mo). Two of 17 patients in this cohort
had no further therapy due to perioperative mortality and 15
had standard chemoradiation post-LITT. For recurrent GBMs
(n = 41), OS was 11.8 mo (95% CI 8.6-13.8 mo, range 0-34.2
mo) and PFS was 7.3 mo (95% CI 5.1-8.9 mo, range 0-32 mo;
Figure 3A and 3B). Of these, 36 had prior open craniotomy and
all 41 had prior standard of care chemoradiation. When calcu-
lated from time of initial histologic diagnosis of GBM, OS for the
recurrent group was 22.3 mo (95% CI 16.2-26.8 mo), compared
to 9.1 mo for the primary group (P < 0.0001; Figure 4). The
difference in survival from time of LITT between primary and
recurrent tumors was not significant (P = 0.31).
Lesions that were deep-seated (corpus callosum, thalamus,
insula) were compared to those in lobar locations. There were 18
deep-seated and 40 lobar lesions. Of the deep lesions, 9 (50%)
were primary treatments and 9 (50%) were recurrences. Of the
lobar lesions, 9 (23%) were primary treatments and 31 (77%)
were recurrences. Median OS after LITT was 11.3 mo (range 0-
34.2mo) for lobar and 11.5mo (range 0-25.4mo) for deep-seated
GBMs (P = 0.68). Median PFS after LITT was 6.8 mo (range
0-32 mo) for lobar and 6.0 mo (range 0-19.3) for deep GBMs
(P = 0.44).
In patients with MGMT, methylation OS was 11.6 mo and
PFS was 6.0 mo, while for unmethylated MGMT OS was 11.1
and PFS was 6.3 mo (P = 0.32 and 0.44, respectively; Figure 5A
and 5B). In patients with EGFR amplification, OS and PFS
were 11.4 and 6.7 mo, respectively, and for those without ampli-
fication, 8.6 and 4.4 mo (P = 0.99 and 0.84, respectively;
Figure 5C and 5D). We did not have sufficiently high numbers
of other genetic markers (such as IDH-1 mutation) to permit
survival analyses.
DISCUSSION
LITT is a minimally invasive surgical tool to treat intracranial
lesions, and offers lower morbidity, shorter length of stay, and
good surgical outcomes.5,17-19 We find LITT to be a safe and
efficacious procedure based on our experience of 58 cases. Of the
two mortalities (3.4%), one was a 78-yr old with a large parieto-
occipital GBM which hemorrhaged after treatment; the patient’s
family elected for comfort measures only. The second patient
developed fulminant Enterobacter meningitis, and analysis of
the event traced this problem to a sterile-processing related
contamination.
Perioperative morbidities were commonly related to cerebral
edema and seizures. It is postulated that patients with larger
tumor volume are predisposed to complications from cerebral
edema and mass effect.20,21 Intuitively, it would seem that larger
volume ablations would result in more cell death, coagulative
necrosis, and release of more inflammatory mediators than
smaller volume ablations. In our series, mean tumor volume
in patients who had complications was 15.5 cm3 while that of
uncomplicated cases was 11.7 cm3; however, this did not reach
significance (P = 0.20). Similarly, tumor location may have
some effect on complication rate, and it might be expected that
deep-seated lesions (corpus callosum, thalamus, insula) have
more complications. Only 13% (5 of 40) of patients with super-
ficial/lobar GBMs experienced a complication, while 22% (4 of
18) patients with deep-seated lesions experienced a complication.
However, this difference also was not significant (P = 0.37).
Median tumor volume was 8.8 cm3 (mean 12.5 cm3, range
0.27-62.8 cm3). Overall, we were able to achieve an average of
93% of tumor volume treatment within the yellow TDT line and
88% treatment with the blue TDT line, concordant with longer
term radiographic results, suggesting that LITT is an effective
cytoreductive option for GBMs that are less favorable for open
surgery.
Follow-up data in this series were largely complete; at the time
of this study, only 8 of 54 patients (14.8%) were alive. For the
total cohort, median PFS after LITT was 6.6 mo and median
OS was 11.5 mo. For frontline GBM treatment, median OS was
9.1 mo, while for recurrent GBM treatment median OS was
11.8 mo. This difference may be in part due to patient selection
for these groups. Patients for whom LITT is chosen as a frontline
therapy were not good candidates for craniotomy, due to deep-
seated lesions, advanced age, poor functional status, or some
combination thereof. Since these patients have a poorer prognosis
from the start, it follows that OS in this group may be shorter.
OS in GBM patients who undergo biopsy only followed
by chemoradiation has been reported by Stupp et al22 to be
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FIGURE 5. A and B, Overall and PFS by MGMT promoter status, and C and D, EGFR amplification status. OS for the MGMT-methylated vs MGMT-unmethylated
group was 11.6 and 11.1 mo, respectively; PFS was 6 and 6.3 mo, respectively. There were no statistically significant differences. OS for the EGFR amplified vs EGFR
nonamplified group was 11.4 and 8.6 mo, respectively; PFS was 6.7 and 4.4 mo, respectively. There were no statistically significant differences.
9.4 mo. In our cohort, the addition of frontline LITT did not
demonstrate a survival benefit (OS 9.1 mo) relative to this
historical outcome data. The frontline LITT cohort had either
deep-seated tumors (ie thalamic, brainstem), or were elderly/frail
with poor performance status; both are poor prognostic factors
in GBM. At this juncture, it is hard to ascertain whether the
biopsy only group from Stupp et al22 is comparable to the
upfront LITT population. It is possible that the upfront LITT
patient population would have fared worse without LITT.
The shorter OS in the frontline LITT group relative to the
recurrence group, from time of diagnosis (9.1 mo vs 22.3 mo,
P < 0.0001), is also evidence that these are very different
patient populations (Figure 4). Ultimately, a randomized
controlled trial would be necessary to formally answer
this question.
For recurrent GBM deemed nonsurgical, treatment modal-
ities include stereotactic radiosurgery (SRS) and additional
chemotherapies. Studies have shown mixed results regarding
the efficacy and safety profile of SRS, though it appears
that certain subgroups of patients—such as those with small
focal recurrence—may benefit.23-25 At our institution, recurrent
GBM patients are typically treated with bevacizumab or repeat
temozolomide, alone or in combination with other chemother-
apeutic drugs. In the recurrent cohort, Friedman et al showed
OS after treatment with bevacizumab to be 9.2 mo,14 and
Desjardins et al26 showed OS after combination bevacizumab
and temozolomide to be 9.3 mo. Numerous other studies have
demonstrated shorter or similar survival figures after a variety
of chemotherapeutic regimens at GBM recurrence.27-29 In our
cohort, the addition of LITT at recurrence resulted in an OS of












11.8 mo. While this is only an additional 2 mo, in the context
of survival after recurrent GBM, this may represent a small but
meaningful survival benefit. Furthermore, this benefit comes with
significantly less operative morbidity and recovery time compared
to traditional craniotomy. Further controlled studies on LITT for
recurrent GBM will be essential as LITT gains acceptance as a
therapy for this group.
We had insufficient data to perform valid survival analyses
with regard to all genetic prognostic markers in GBM except
MGMT methylation. Of 45 patients for whom MGMT data
were available, 21 were methylated. OS in the methylated
group after LITT was 11.6 compared with 11.1 for unmethy-
lated (log rank P = 0.32). Significantly improved survival in
the MGMT-methylated group is not seen in this cohort, as
may be expected from previous literature.30-32 One explanation
is that MGMT methylation confers greater responsiveness to
chemotherapy initially, but these cells are selectively eliminated
and not present in recurrent tumors. It is also possible that this
equivalence in survival between these two cohorts is related to
the difference in how LITT affects the biology of the tumor and
local environment. Hypermethylation of the MGMT gene has
been shown to be associated with improved outcome in GBM and
may be a predictive marker of sensitivity to alkylating agents and
radiotherapy.22,32 Thus, the lack of methylation makes GBMs
less susceptible to chemoradiation. LITT has been shown to be
effective at breaking down the blood brain barrier in humans,7
and hyperthermia has been shown to enhance radiosensitivity in
glioma stem cells by altering the PI3-AKT inducing pathway,
which is aberrantly regulated in more than 40% of GBM and
associated with poor patient prognosis.33 Taken together, the
equivalent outcome for LITT in MGMT unmethylated patients
may represent that this susceptibility is to some degree compen-
sated by the biological effects of LITT.
Limitations
Limitations of this study are those inherent to a single-
institution series. The cases were performed by two surgeons at
a single center, and may not be generalizable to all centers that
perform LITT. Additionally, treatment of GBM is a complex
process individualized to the patient. We included data about
surgery, radiotherapy, and chemotherapy as the standards of care;
however, we did not control for themyriad clinical trials, research-
phase drugs, and devices (e.g. Optune R©; Novocure, St. Helier,
United Kingdom) that may have played a role in these patients’
care. Finally, this is a descriptive study. While LITT offers several
advantages over craniotomy, a comparative study with matched
groups would directly compare the efficacy of the two treatments.
Further studies examining LITT in this context will be useful.
CONCLUSION
Our experience suggests that LITT is a safe, well-tolerated and
efficacious cytoreductive treatment for GBM in properly selected
patients.
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T he authors present a single-center retrospective analysis of 54 GBMpatients treated with MRI-guided LITT over a 6-year period. They
find that LITT is an effective therapy that may extend life expectancy
in patients with recurrent GBM who are not candidates for re-resection
due to age, medical co-morbidities, or poor functional status. The paper
extends substantively the published experience with LITT for GBM,
helping to define its appropriate use.
Ron L. Alterman
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I n this study, authors present outcomes from over 50 patients withglioblastoma treated with Laser Interstitial Thermal Therapy (LITT).
This is one of the largest series available, with essentially complete
follow-up data. The majority of the treatments (about 70%) were
for recurrent glioblastoma, while the remainder (about 30%) were
for newly-diagnosed glioblastoma, for which the pathology was deter-
mined by biopsy. Median overall survival was 11.5 months, while
median progression-free survival was 6.6 months. There were 9 compli-
cations within 30 days of the procedure (15.5%), mostly related to
cerebral edema and seizures. There were 2 mortalities (3.4%) secondary
to post-treatment hemorrhage (possibly related to tumor size) and to
infection from instrument contamination. Based on the data in this
study, LITT appears to have particular value for patients with recurrent
glioblastoma who may be too medically frail and/or have lesions that are
too deep-seated for safe surgical resection. In these cases, average overall
median survival was about 2 months longer than comparable cohorts
using bevacizumab. While relatively small, the difference is nonetheless
meaningful given the decreased recovery time compared to a traditional
craniotomy. Overall, the study is well-written and adds to the body of
literature on available treatment modalities for glioblastoma
Emanuela Binello
Boston, Massachusetts
T he authors present outcomes from glioblastoma patients treated withLaser Interstitial Thermal Therapy (LITT). With 58 LITT treat-
ments (17 for newly diagnosed GBM confirmed by biopsy either previ-
ously or concurrently with LITT) in 54 GBM patients, this is one of
the largest series available, with good long-term follow-up. Progression-
free survival was 6.6 months and overall survival was 11.5 months.
Adverse events mostly involved cerebral edema and seizures.The 30-day
treatment-related morbidity rate was 16% and there were 2 treatment-
related mortalities (3%), 1 from post-LITT hemorrhage in a large
tumor and the other from infection due to contaminated instruments.
Choice of LITT was due to tumor location precluding surgery in one-
third of LITT cases and due to age or functional status in two-thirds
of cases. In these cases, average overall survival was about 2 months
longer than similar published cohorts treated with bevacizumab. The
authors are to be commended on this well-written study, which adds
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